US FDA authorizes additional batch of J&J jabs produced at Baltimore factory | World News - Hindustan Times
close_game
close_game

US FDA authorizes additional batch of J&J jabs produced at Baltimore factory

Reuters |
Jul 03, 2021 02:05 AM IST

"While the FDA is not yet ready to include the Emergent BioSolutions plant ... as an authorized manufacturing facility, the agency continues to work through issues there with Janssen and Emergent BioSolutions management," the FDA said.

The US Food and Drug Administration said on Friday it had authorized the use of an additional batch of Johnson & Johnson's one-dose Covid-19 vaccine manufactured at the problem-plagued Baltimore factory of Emergent BioSolutions Inc.

The FDA has now authorized a total of four batches of the vaccine manufactured at the Emergent facility.(AFP)
The FDA has now authorized a total of four batches of the vaccine manufactured at the Emergent facility.(AFP)

The batch of bulk drug substance - which has not yet been put into vials - can make up to 15 million doses of J&J's vaccine, according to a source familiar with the matter.

Hindustan Times - your fastest source for breaking news! Read now.

The FDA has now authorized a total of four batches of the vaccine manufactured at the Emergent facility.

"While the FDA is not yet ready to include the Emergent BioSolutions plant ... as an authorized manufacturing facility, the agency continues to work through issues there with Janssen and Emergent BioSolutions management," the agency said in a statement, referring to J&J's pharmaceuticals unit.

Production of J&J's vaccine at the Baltimore site was halted by US authorities in April following the discovery that ingredients from AstraZeneca's Covid-19 vaccine, also being produced at the plant at the time, contaminated a batch of J&J's vaccine.

An FDA inspection of the plant also turned up a long list of sanitary problems and bad manufacturing practices.

"As Covid-19 continues to impact countries and cause untold suffering worldwide, we remain committed to producing safe, high-quality vaccines," J&J said in a statement.

J&J shares closed up about 2% at $168.98.

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away! - Login Now!

Get Latest World News along with Latest News from India at Hindustan Times.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, March 29, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On